emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.
Company profile
Ticker
EMMA
Exchange
Website
CEO
Yutaka Niihara
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AGE RESEARCH INC, CNS RESPONSE, INC., MYnd Analytics, Inc., SalesTactix, Inc., STRATIVATION, INC.
SEC CIK
Corporate docs
Subsidiaries
EMI Holding, Inc. • Emmaus Medical, Inc. • Emmaus Medical Japan, Inc. • Newfield Nutrition Corporation • Emmaus Medical Europe Limited • Emmaus Life Sciences, Co. Ltd. • EJ Holdings, Inc. ...
IRS number
870419387
EMMA stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Feb 24
8-K
Entry into a Material Definitive Agreement
19 Dec 23
8-K
Emmaus Life Sciences Reports Q3 2023 Financial Results
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Departure of Directors or Certain Officers
4 Oct 23
8-K
Emmaus Life Sciences Reports Management Changes
23 Aug 23
8-K
Emmaus Life Sciences Reports Q2 2023 Financial Results
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
15 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.51 mm | 1.51 mm | 1.51 mm | 1.51 mm | 1.51 mm | 1.51 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 122.08 k | (no burn) | 71.83 k |
Cash used (since last report) | n/a | n/a | n/a | 842.60 k | n/a | 495.78 k |
Cash remaining | n/a | n/a | n/a | 662.40 k | n/a | 1.01 mm |
Runway (months of cash) | n/a | n/a | n/a | 5.4 | n/a | 14.0 |
Institutional ownership, Q3 2023
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.30 bn |
Total shares | 121.17 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Column Capital Advisors | 43.48 k | $1.19 bn |
Essex Financial Services | 31.42 k | $860.84 mm |
Gibson Capital | 15.63 k | $428.13 mm |
Future Financial Wealth Managment | 10.33 k | $283.15 mm |
Horan Securities | 8.83 k | $241.92 mm |
Parallel Advisors | 6.50 k | $178.10 mm |
Colonial Trust Advisors | 4.20 k | $115.05 mm |
NBC Securities | 771.00 | $21.00 k |
Farther Finance Advisors | 9.00 | $247.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | Yes | No | 0.13 | 77,000 | 10.01 k | 159,400 |
28 Feb 24 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | Yes | No | 0.12 | 15,000 | 1.80 k | 82,400 |
27 Feb 24 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | Yes | No | 0.13 | 10,000 | 1.30 k | 67,400 |
26 Feb 24 | Lee Willis C | Common stock, $0.001 par value | Buy | Acquire P | Yes | No | 0.12 | 13,200 | 1.58 k | 57,400 |
1 Feb 24 | Lee Willis C | Options Common Stock | Grant | Acquire A | No | No | 0.15 | 200,000 | 30.00 k | 200,000 |
1 Feb 24 | Yasushi Nagasaki | Options Common Stock | Grant | Acquire A | No | No | 0.15 | 200,000 | 30.00 k | 200,000 |
1 Feb 24 | George Sekulich | Options Common Stock | Grant | Acquire A | No | No | 0.15 | 200,000 | 30.00 k | 200,000 |
1 Feb 24 | Seah H. Lim | Options Common Stock | Grant | Acquire A | No | No | 0.15 | 100,000 | 15.00 k | 100,000 |